Table 4

Logistic regression analysis examining the relation of proteins with prevalent atrial fibrillation

OR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P value
Model 1Model 2Model 3
NT-proBNP4.24 (3.37 to 5.33)3.56×10–354.38 (3.42 to 5.61)9.81×10–323.83 (2.93 to 5.02)1.71×10–22
PON30.65 (0.54 to 0.78)2.75×10–60.66 (0.55 to 0.80)1.16×10–50.68 (0.55 to 0.84)3.15×10–4
TNFR11.11 (0.90 to 1.35)0.3240.95 (0.77 to 1.18)0.6580.80 (0.63 to 1.00)0.050
IGFBP-71.49 (1.22 to 1.83)1.24×10–41.37 (1.11 to 1.68)0.0031.21 (0.96 to 1.51)0.102
FABP41.51 (1.23 to 1.86)8.73×10–51.49 (1.19 to 1.87)0.0011.17 (0.90 to 1.53)0.247
OPN1.38 (1.11 to 1.71)0.0041.23 (0.99 to 1.54)0.0651.13 (0.90 to 1.43)0.300
MMP-21.33 (1.07 to 1.66)0.0111.20 (0.96 to 1.50)0.1101.10 (0.87 to 1.40)0.420
GAL-41.38 (1.11 to 1.71)0.0031.23 (0.98 to 1.53)0.0680.95 (0.74 to 1.21)0.661
UPAR1.30 (1.05 to 1.60)0.0141.13 (0.91 to 1.41)0.2670.95 (0.75 to 1.21)0.672
GDF-151.51 (1.24 to 1.85)4.73×10–51.27 (1.02 to 1.58)0.0331.03 (0.80 to 1.33)0.813
CHI3L11.21 (0.99 to 1.48)0.0661.07 (0.87 to 1.33)0.5050.99 (0.79 to 1.24)0.931
  • Values are ORs and 95% CI for prevalent atrial fibrillation. Model 1 is unadjusted. Model 2 is age and sex adjusted. Model 3 is further adjusted for body mass index, systolic blood pressure, smoking status, prevalent diabetes mellitus, prevalent coronary events, prevalent heart failure and antihypertensive treatment.

  • CHI3L1, chitinase-3-like protein 1; FABP4, fatty-acid binding protein 4; GAL-4, galectin 4; GDF-15, growth differentiation factor 15; IGFBP-7, insulin-like growth factor-binding protein 7; MMP-2, matrix metalloproteinase-2; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OPN, osteopontin; PON3, paraoxonase 3; TNFR1, tumour necrosis factor receptor 1; UPAR, urokinase receptor.